Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $58.50.

Several research analysts recently weighed in on OMCL shares. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a report on Wednesday, January 7th. Wall Street Zen lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Zacks Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Wells Fargo & Company upped their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Wednesday, February 4th.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. This represents a 7.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd purchased a new position in Omnicell in the second quarter valued at about $2,692,000. Advantage Alpha Capital Partners LP purchased a new stake in shares of Omnicell during the 2nd quarter worth approximately $2,476,000. Assenagon Asset Management S.A. increased its stake in shares of Omnicell by 1,316.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after purchasing an additional 130,742 shares during the last quarter. Capital Fund Management S.A. raised its holdings in shares of Omnicell by 97.1% in the 2nd quarter. Capital Fund Management S.A. now owns 44,713 shares of the company’s stock worth $1,315,000 after purchasing an additional 22,031 shares during the period. Finally, Systematic Financial Management LP bought a new stake in shares of Omnicell in the 2nd quarter worth approximately $3,446,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 3.7%

NASDAQ OMCL opened at $34.31 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The business has a fifty day simple moving average of $41.97 and a 200 day simple moving average of $38.56. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.00. The firm has a market capitalization of $1.56 billion, a P/E ratio of 857.96, a PEG ratio of 1.19 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, analysts predict that Omnicell will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.